Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Lucid Diagnostics (LUCD)
NASDAQ:LUCD
Holding LUCD?
Track your performance easily
LUCD Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.63 - $1.58
Previous Close$1
Volume643.14K
Average Volume (3M)297.47K
Market Cap
$59.28M
Enterprise Value$33.54M
Total Cash (Recent Filing)$39.52M
Total Debt (Recent Filing)$13.78M
Price to Earnings (P/E)―
Beta0.37
Next Earnings
Mar 31, 2025EPS Estimate
-$0.18Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.13
Shares Outstanding59,342,479
10 Day Avg. Volume695,290
30 Day Avg. Volume297,472
Standard Deviation0.18
R-Squared0.16
Alpha-0.06
Financial Highlights & Ratios
Price to Book (P/B)5.26
Price to Sales (P/S)89.46
Price to Cash Flow (P/CF)-2.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue52.90
Enterprise Value/Gross Profit88.96
Enterprise Value/Ebitda-0.58
Forecast
1Y Price Target
$3.54Price Target Upside254.35% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
Lucid Diagnostics News
PremiumCompany Announcements
Lucid Diagnostics Reports Q3 Revenue Growth and Strategic ExpansionPremiumCompany Announcements
Lucid Diagnostics Reports Revenue Growth and Secures Funding
PremiumCompany Announcements
Lucid Diagnostics Announces Convertible Notes Exchange Initiative
Bulls Say, Bears Say
Bulls Say
Commercial Strategy And Revenue PotentialLucid Diagnostics has expanded its direct contracting initiative, particularly in the concierge medicine sector, which is a new commercial channel for LUCD and offers attractive revenue potential.
Medicare Coverage And Market PotentialLucid Diagnostics is actively pursuing Medicare coverage, which could also catalyze private payor coverage and contribute significantly to the company's growth.
Revenue Growth And Market ExpansionLucid's efforts to deepen its market penetration through a comprehensive strategy should drive revenue higher over time, supported by the generation and publication of clinical evidence to obtain broader coverage for its novel esophageal cancer screening approach.
Bears Say
Financial PerformanceLUCD's operating expenses were above estimate.
Market ConcernsLucid Diagnostics currently has a small market cap, which may concern some investors despite the potential catalysts on the horizon.
Operational PerformanceLucid's processed test volume materially decreased, partially driven by summer seasonality headwinds.
---
Ownership Overview
58.35% Insiders
1.28% Mutual Funds
2.31% Other Institutional Investors
37.12% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
LUCD FAQ
What was Lucid Diagnostics’s price range in the past 12 months?
Lucid Diagnostics lowest stock price was $0.63 and its highest was $1.58 in the past 12 months.
What is Lucid Diagnostics’s market cap?
Currently, no data Available
When is Lucid Diagnostics’s upcoming earnings report date?
Lucid Diagnostics’s upcoming earnings report date is Mar 31, 2025 which is in 128 days.
How were Lucid Diagnostics’s earnings last quarter?
Lucid Diagnostics released its earnings results on Nov 13, 2024. The company reported -$0.2 earnings per share for the quarter, beating the consensus estimate of -$0.206 by $0.006.
Is Lucid Diagnostics overvalued?
According to Wall Street analysts Lucid Diagnostics’s price is currently Undervalued.
Does Lucid Diagnostics pay dividends?
Lucid Diagnostics does not currently pay dividends.
What is Lucid Diagnostics’s EPS estimate?
Lucid Diagnostics’s EPS estimate is -$0.18.
How many shares outstanding does Lucid Diagnostics have?
Lucid Diagnostics has 59,342,480 shares outstanding.
What happened to Lucid Diagnostics’s price movement after its last earnings report?
Lucid Diagnostics reported an EPS of -$0.2 in its last earnings report, beating expectations of -$0.206. Following the earnings report the stock price went up 5%.
Which hedge fund is a major shareholder of Lucid Diagnostics?
Currently, no hedge funds are holding shares in LUCD
---
Lucid Diagnostics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$3.54 (254.35% Upside)
$3.54 (254.35% Upside)
Blogger Sentiment
Bullish
LUCD Sentiment 100%
Sector Average 72%
Sector Average 72%
Crowd Wisdom
Very Positive
Last 7 Days ▲ 3.4%
Last 30 Days ▲ 4.5%
Last 30 Days ▲ 4.5%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-23.15%
12-Months-Change
Fundamentals
Return on Equity
-1007.83%
Trailing 12-Months
Asset Growth
-32.02%
Trailing 12-Months
Company Description
Lucid Diagnostics
Lucid Diagnostics Inc is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease, also known as chronic heartburn, acid reflux or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma.
---
LUCD Earnings Call
Q3 2024
0:00 / 0:00
---
LUCD Stock 12 Month Forecast
Average Price Target
$3.54
▲(254.35% Upside)
Technical Analysis
Best Analysts Covering LUCD
1 Year
1 Year Success Rate
5/18 ratings generated profit
1 Year Average Return
-28.39%
reiterated a buy rating 10 days ago
Copying Michael Matson's trades and holding each position for 1 Year would result in 27.78% of your transactions generating a profit, with an average return of -28.39% per trade.
---